Dong-A Buoys Female Care Portfolio With Bayer OTCs
This article was originally published in PharmAsia News
In the first move by a South Korean pharma firm to acquire global brand drugs, Dong-A Pharm has taken over four oral contraceptive products from Bayer Korea to beef up its OTC business and female product portfolios.
You may also be interested in...
HanAll and Daewoong remain upbeat on dry eye candidate HL036 and are gearing up for a second Phase III US study despite the first missing its primary endpoint in just-released top-line results.
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.